New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
09:27 EDTGEVOGevo wins patent suit in Delaware Court
Gevo announced that a judgment of non-infringement will be entered for Gevo following the acknowledgment by Butamax Advanced Biofuels that Gevo does not infringe Butamax's asserted patents under the Court's construction of a key claim term in Butamax's Patent Nos. 7,851,188 and 7,993,889. As a result of this victory, a judgment of non-infringement will be entered in Gevo's favor and the trial scheduled for April 1 will no longer take place. The judgment of non-infringement comes on the heels of the Court's important claim construction determination which held that Butamax's Patents 7,851,188 and 7,993,889 require the use of an "NADPH-dependent" KARI. Butamax conceded that it could not establish that Gevo's KARI is NADPH-dependent.
News For GEVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
18:21 EDTGEVOOn The Fly: After Hours Movers
Subscribe for More Information
16:04 EDTGEVOGevo files to sell common stock and warrants
Gevo announced that it intends to offer and sell, subject to market and other conditions, common stock units. Each common stock unit will consist of one share of common stock, Series A warrants to purchase a certain number of shares of common stock and Series B warrants to purchase a certain number of shares of common stock. The units are to be sold by Gevo subject to market and other conditions in an underwritten public offering. Cowen and Company, LLC is acting as sole manager.
January 27, 2015
09:10 EDTGEVOGevo announces Supreme Court rules in favor of Gevo
Gevo (GEVO) announced that the U.S. Supreme Court ruled in Gevo's favor and overturned an earlier Federal Circuit Court of Appeals ruling on the interpretation of key patent claims. The result is that Gevo's victory in the Delaware District Court is reinstated, and that the case has been remanded back to the Appeals Court for consideration in light of the new standard of appellate review that was decided in the Teva Pharmaceuticals USA, Inc., v. Sandoz, Inc. case last week. In Teva (TEVA), the Supreme Court ruled that the Appeals Court must apply a more stringent "clear error" standard of review, rather than a "de novo" standard of review. In Gevo's case, the Appeals Court must now apply the "clear error" standard of review and cannot set aside the Delaware District Court's findings of fact in Gevo's favor unless they were clearly erroneous. The Supreme Court's decision effectively reinstates Gevo's victory at the District Court where a final judgment of non-infringement was entered in Gevo's favor following the acknowledgment by Butamax Advanced Biofuels LLC that Gevo does not infringe Butamax's Patent Nos. 7,851,188 and 7,993,889.
January 20, 2015
08:46 EDTGEVOGevo announces headcount reduction at headquarters among other measures
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use